时间趋势分析和尼拉巴诱导的卵巢癌中恶心和吐的危险因素:一项前性研究
Young Wook Jeong1, Dongkyu Eugene Kim1,2, Ji Hyun Kim1
1Center for Gynecologic Cancer, National Cancer Center, Goyang, Korea.
Cancer research and treatment
|November 8, 2024
概括
尼拉帕里布维持疗法可能导致恶心和吐 (NINV). 这项研究发现同源复合缺陷 (HRD) 和先前化疗诱导的恶心和吐增加了卵巢癌患者的NINV风险.
科学领域:
- 在瘤学瘤学.
- 药理学 药理学是指药理学的学科.
- 临床研究 临床研究
背景情况:
- 恶心和吐是尼拉帕里布维持治疗的显著非血液学不良事件.
- 了解尼拉巴里布诱导的恶心和吐 (NINV) 的时间模式和风险因素对于患者管理至关重要.
研究的目的:
- 为了研究接受niraparib的卵巢癌患者NINV的时间趋势模式.
- 为了确定与尼拉帕里布维持治疗期间NINV发生相关的风险因素.
主要方法:
- 对53名患者进行前性研究,这些患者患有III-IV期上皮卵巢癌,正在接受niraparib维持治疗.
- 数据收集包括临床病理学特征和NINV时间趋势模式通过调查和电子医疗记录.
- 进行了多变量分析,以确定NINV.的风险因素.
主要成果:
- NINV发生在58.5%的患者中,剂后3小时和11小时达到峰值强度.
- 从第1周到第8周和第12周,NINV强度显著下降.
- HRD阳性瘤 (p<0.001) 和先前的化疗诱导的恶心和吐 (p=0.004) 是NINV的显著风险因素.
结论:
- 预防性抗治疗对于早期的NINV是必要的,特别是在具有已确定的风险因素的患者中.
- 需要进行更大规模的研究来证实这些发现,并制定针对NINV.的最佳预防策略.
相关概念视频
Chemotherapy-Induced Nausea and Vomiting: Neurokinin-1 Receptor Antagonists
148
Neurokinin 1 (NK1) receptors are distributed across the GI tract, vagal afferents, and key CNS regions including the central vomiting center and chemoreceptor trigger zone (CTZ) Chemotherapy agents stimulate enterochromaffin cells in the gastrointestinal (GI) tract to release large amounts of substance P (SP). SP is a neuropeptide released by specific sensory nerves in response to many different stressors, including those in the GI mucosa affected by chemotherapy. SP binds and activates...
148
Chemotherapy-Induced Nausea and Vomiting: 5-HT3 Receptor Antagonists
174
5-HT3 receptor antagonists, such as dolasetron, granisetron (Kytril), ondansetron (Zofran), and palonosetron (Axoli), are crucial in managing chemotherapy-induced nausea and vomiting (CINV) and postoperative nausea. These drugs selectively block 5-HT3 receptors in the visceral vagal and spinal afferent nerves, chemoreceptor trigger zone, and the vomiting center. They have a rapid onset of action and can be given as a single dose before chemotherapy. Ondansetron and granisetron, in particular,...
174
Chemotherapy-Induced Nausea and Vomiting: Cannabinoids
202
Tetrahydrocannabinol (THC) is a phytocannabinoid that primarily interacts with the CB1 receptor, a type of G protein-coupled receptor (GPCR) predominantly in and around the chemoreceptor trigger zone (CTZ) and emetic center. THC also blocks the serotonin receptor activity in the dorsal vagal complex (DVC) by inhibiting serotonin release. THC exerts its anti-emetic effects through these interactions, which are beneficial for patients undergoing chemotherapy.
Two synthetic agonists of THC,...
Two synthetic agonists of THC,...
202
Cancer Survival Analysis
328
Cancer survival analysis focuses on quantifying and interpreting the time from a key starting point, such as diagnosis or the initiation of treatment, to a specific endpoint, such as remission or death. This analysis provides critical insights into treatment effectiveness and factors that influence patient outcomes, helping to shape clinical decisions and guide prognostic evaluations. A cornerstone of oncology research, survival analysis tackles the challenges of skewed, non-normally...
328
mTOR Signaling and Cancer Progression
3.7K
The mammalian target of rapamycin or mTOR protein was discovered in 1994 due to its direct interaction with rapamycin. The protein gets its name from a yeast homolog called TOR. The mTOR protein complex in mammalian cells plays a major role in balancing anabolic processes such as the synthesis of proteins, lipids, and nucleotides and catabolic processes, such as autophagy in response to environmental cues, such as availability of nutrients and growth factors.
The mTOR pathway or the...
The mTOR pathway or the...
3.7K


